| For more information on our LVAD Program: |
832-355-3285 |
| International Patients: |
832-355-3350 |
The Left Ventricular Assist Device (LVAD) Program at St. Luke’s Episcopal Hospital, home of the Texas Heart Institute, is one of the most experienced, successful programs in the world. Our surgeons have performed more than 828 LVAD procedures. The key to the program’s success is an experienced, highly skilled team that includes surgeons, cardiologists, LVAD coordinators, staff nurses, operating room personnel, social workers, dieticians, rehabilitation specialists, and many other professionals.
MILESTONES
| |
1975 |
First study funded buy the National Heart, Lung and Blood Institute of an implantable left ventricular assist device (LVAD) for post-cardiotomy support |
|
| |
1978 |
First bridge-to-transplant with an LVAD |
|
| |
1988 |
First implantable continuous flow LVAD implanted – The Hemopump developed at the Texas Heart Institute |
|
| |
1991 |
First patient in the world left the hospital with an electric, portable, battery-powered LVAD |
|
| |
1994 |
FDA approval to use the HeartMate® pneumatic LVAD as a bridge to transplantation (BTT), a treatment option for patients suffering from advanced-stage heart failure |
|
| |
1996 |
FDA approval to use the HeartMate® vented electric as a bridge to transplantation (BTT) |
|
| |
2000 |
First site for clinical trials of the Jarvik 2000, a miniature, axial flow left ventricular assist device |
|
| |
2001 |
Completed REMATCH study, which compared long-term implantation of the HeartMate® VE electric LVAD to conventional medical therapy for heart failure |
|
| |
2002 |
HeartMate® VE electric LVAD approved for destination therapy |
|
| |
2003 |
First implantation of the clinical HeartMate® II LVAD; currently the most widely used continuous flow LVAD in the world. |
|
| |
2004 |
First United States patient to receive HeartMate® II LVAD surpasses one year of survival with the device |
|
| |
2008 |
HeartMate® II Left Ventricular Assist System (LVAD) received FDA approval as a bridge-to-transplant (BTT) treatment option for patients suffering from advanced-stage heart failure |
|
| |
2010 |
FDA approves HeartMate® II LVAD as Destination Therapy |
|
- Destination Therapy is a permanent option for patients with heart failure who are not candidates for heart transplantation.
- BTT (Bridge to Transplantation) is a treatment option in which an LVAD is used while a patient is waiting for a heart donor
The Texas Heart Institute at St. Luke's Episcopal Hospital
The Heart Exchange Transplant Support Group
Donate Life Texas
Donate Life America
Lodging close to St. Luke's Episcopal Hospital
Parking close to St. Luke's Episcopal Hospital
LVAD and Heart Pumps
Kidney Transplant Program
Liver Transplant Program
Heart Transplant Program
